Implements digital front door, stock steady
This News Digest Is BROUGHT TO YOU BY
THE FDA CONSULTANTS, LLC
BY: LISA MUNGER
Monash IVF has been one of the largest IVF providers in Australia for more than 40 years.
Monash offers various services, including IVF, donor programs and fertility preservation. Recently, its stock has been featured in international media
Stock Steady, Speculation Raises Profile
Recent stock reports suggest that Monash is a strong investment opportunity with the potential for significant growth in the coming years. The company went public in June 2014 with CEO Michael Knapp.
The company's shares could be worth as much as AU $1.81 compared to their current trading price of AU $1.16, according to analysts with Simply Wall Street.
The report used a discounted cash flow model to estimate the company's intrinsic value by forecasting future cash flows and discounting them to their present value. The model assumes that Monash will experience two stages of growth, with a higher growth rate in the initial period and a stable growth rate in the second stage.
The report estimates that Monash IVF Group's free cash flow will increase from AU $5.45 million in 2023 to AU $42.2 million in 2032, with a growth rate of between 2.32 and 5.27%. The present value of these cash flows, discounted at a rate of 6.7%, is estimated to be AU $233 million.
The report also noted that the analyst price target for Monash IVF Group is AU $1.32, which is 27% less than the estimated fair value of AU $1.81.
Monash’s stock hit its highest point ever in July 2016 at $2.54 USD. By contrast, on May 2, 2023, the stock hit its highest point in the last year, starting the opening bell at $1.60 USD, according to Rask Media.
New Technology Implemented
In 2020, Monash became the first clinic in Australia to offer a new genetic screening technique called karyomapping, which can identify genetic disorders in embryos before they are implanted. By using this technique, Monash aims to reduce the risk of genetic disorders in children born through IVF.
The company has implemented a digital front door, which is a digital interface that optimizes the collection and sharing of critical information with patients throughout their treatment, thus increasing accessibility.
The portal offers patients various services and information, including the ability to schedule appointments, access medical records, receive personalized treatment plans and access educational resources about fertility treatments.
The digital front door is a centralized platform that enhances patient engagement, facilitates communication and ensures that individuals are well-informed throughout their fertility journey.
Monash partnered with Personify Care to set up digital patient pathways, allowing patients to access their treatment plans, communicate with their care team, and receive reminders and education materials through a mobile app.
PIVET
Monash acquired PIVET Medical Centre (PIVET), a leading fertility provider headquartered in Pert, in May 2022. The initial upfront cost of the acquisition was set at $9.4 million USD.
PIVET played a role in Western Australia's first successful IVF birth in 1982. Over the years, PIVET has expanded its operations and extended its services to Cairns in 2009. PIVET has assisted in the birth of more than 8,000 babies through its comprehensive range of treatments, according to Business News Australia.
The acquisition, which is due to be completed during the third quarter of FY23, is expected to be funded through Monash IVF's operating cash flows and/or available debt facilities of $105 million.
Currently generating annual revenues of approximately $8 million, PIVET may be entitled to additional earnouts depending on its performance over a one-to-two-year period following the deal's completion, according to the report. The deal was supposed to have been completed by projected to conclude by the end of September 2022, as of the latest update in February 2023.
Neither Monash IVF nor Michael Knapp responded to Inside Fertility Health’s requests for comment for this story.
The themes reported in this publication are those of the news. They do not reflect the views of Inside Reproductive Health, nor of the Advertiser
These 5 Deficiencies Lead to FDA Nightmare
HCLD IVF lab director comes together with reproductive health attorney to make checklist of what she wishes she had known about what the FDA is looking for in the IVF lab.
Download their free FDA checklist for the five most common IVF lab deficiencies before the FDA audits you.
All external links active as of 7/6/23.
External links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Fertility Bridge or Inside Reproductive Health of any of the products, services or opinions of the corporation or organization or individual. Neither Fertility Bridge nor Inside Reproductive Health bears responsibility for the accuracy, legality or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.